


BK Medical ApS

Mileparken 34, 2730 Herlev

CVR No. 15 73 11 76

Annual report for the year ended 31 July 2019

Adopted at the annual general meeting
on 13 December 2019



.....
chairman

Contents

Company details	1
Statement by management on the annual report	2
Independent auditor's report	3
<i>Independent auditors' report on the financial statements</i>	
Financial highlights	6
Management's review	7
<i>Financial statements</i>	
Accounting policies	12
Income statement	20
Balance sheet	21
Notes	23

Company details

BK Medical ApS
Mileparken 34
2730 Herlev
www.bkmedical.com
Tel: +45 44 52 81 00

Supervisory board

Brooks Edward West, chairman
Robert Joseph Patterson
Dorthe Lundby Pedersen
Jens Mose Pedersen
Steen Madsen

Executive board

Bo Hansen
Daniel Banemann

Parent

BK Medical Holding ApS
CVR No. 27 97 14 07

Auditors

Deloitte Statsautoriseret Revisionspartnerselskab
Weidekampsgade 6, 2300 København S, Denmark

Bankers

Danske Bank
Munkeengen 30, 3400 Hillerød, Denmark

Statement by management on the annual report

Today, the Supervisory Board and the Executive Board have discussed and approved the annual report of BK Medical ApS for the financial year 1 August 2018 - 31 July 2019.

The annual report is prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the company's financial position at 31 July 2019 and of the results of its operations for the financial year 1 August 2018 - 31 July 2019.

Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.


We recommend the adoption of the annual report at the annual general meeting.

Herlev, 13 December 2019

Executive board:




Bo Hansen



Daniel Banemann

Supervisory board:



Brooks Edward West
chairman



Dorthe Lundby Pedersen



Robert Joseph Patterson



Jens Mose Pedersen



Steen Madsen

Independent auditor's report

To the shareholders of BK Medical ApS

Opinion

We have audited the financial statements of BK Medical ApS for the financial year 01.08.2018 - 31.07.2019, which comprise the income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Entity's financial position at 31.07.2019 and of the results of its operations for the financial year 01.08.2018 - 31.07.2019 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditor's responsibilities for the audit of the financial statements section of this auditor's report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Entity's ability to continue as a going concern, for disclosing, as applicable, matters related to going concern, and for using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statement

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements, and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures in the notes, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the management commentary

Management is responsible for the management commentary.

Our opinion on the financial statements does not cover the management commentary, and we do not express any form of assurance conclusion thereon.


In connection with our audit of the financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the management commentary provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the management commentary is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the management commentary.

Copenhagen, 13 December 2019

Deloitte Statsautoriseret Revisionspartnerselskab



Flemming Larsen
state authorized public accountant
MNE no. 27790

Financial highlights

5-year summary:

	2018/19	2017/18	2016/17	2015/16	2014/15
Key figures (in DKK thousands, except number of employee's data and ratios)					
Revenue	407.902	406.187	310.408	329.714	382.752
Gross profit	223.211	246.531	163.640	177.789	199.595
Profit/loss before net financials (EBIT)	64.532	105.078	13.927	30.056	-24.521
Net financials	5.011	4.589	935	3.218	-14.773
Net profit/loss for the year	60.281	85.939	11.436	19.942	-47.523
Balance sheet					
Total assets	415.487	367.709	324.843	338.130	425.988
Equity at year-end	331.907	271.614	226.311	229.875	224.951
Investments in property, plant and equipment	6.036	4.976	10.465	8.836	2.604
Investments in intangible assets	4.422	10.138	17.216	20.230	14.436
Number of employees	130	123	129	137	146
Ratios					
Gross margin	54,7 %	60,7 %	52,7 %	53,9 %	52,1 %
EBIT margin	15,8 %	25,9 %	4,5 %	9,1 %	-6,4 %
Return on assets	15,5 %	28,6 %	4,3 %	8,9 %	-5,8 %
Solvency ratio	79,9 %	73,9 %	69,7 %	68,0 %	52,8 %
Return on equity	20,0 %	31,6 %	5,1 %	8,7 %	-15,9 %

Financial ratios are calculated in accordance with the Danish Finance Society's guidelines on the calculation of financial ratios "Recommendations and Financial Ratios". For terms and definitions, please see the accounting policies.

Management's review

Main activity

BK Medical ApS develops and markets human diagnostic ultrasound equipment, primarily for the urological and surgical market segments and, secondarily, for selected point-of-care markets, general Imaging and other markets. The goal of the Company is to ensure profitable, organic growth exceeding the market growth of these niches, thus ensuring an increased market share. The products are manufactured in the US by the parent company, as well as other companies within the Analogic Group.

Development in the financial year

The Company's revenue for the financial year 2018/19 was DKK 407.9 million, an increase of 0.4 % from 2017/18 when revenue amounted to DKK 406.2 million. We expected the revenue for 2018/19 to be flat with a low single digit organic growth rate. The increase in revenue is primarily attributed to higher direct sales in both Europe and the USA, countered by a decrease in our intercompany revenue.

The operating expenses for 2018/19 increased to DKK 158.7 million compared to an expense of DKK 141.5 million in 2017/18. This is in line with the expectation for the year. The increase relates to a significant increase in our Research and development department.

In 2018/19, the Company realised a profit before tax of DKK 69.5 million compared to a profit before tax of DKK 109.7 million in 2017/18. The decrease is primarily attributed to the decrease in intercompany revenue and increase in operating expenses as mentioned above.

Tax for the year amounted to an expense of DKK 9.3 million in 2018/19 compared to an expense of DKK 23.7 million in 2017/18. Thus, for 2018/19, net profit for the year amounted to DKK 60.3 million compared to a net profit of DKK 85.9 million in 2017/18.

The result for the year is considered satisfactory.

Capital expenditure

The Company's capital expenditure amounted to DKK 6.0 million in property, plant and equipment compared to DKK 5.0 million last year and DKK 4.4 million in intangible assets compared to DKK 10.1 million last year.

Special risks – operating risks and financial risks

Foreign exchange risks

For several years, the Company has aimed at balancing its net positions (sales, purchases, operating expenses and financing expenses), primarily concerning USD, thus reducing the foreign exchange risk significantly. No forward hedging of exchange rate exposures on foreign exchange positions has been entered into.

The results, cash flow and equity of the Company are affected by the development in exchange rates of several different currencies due to the international activities of the Company.

Management's review (continued)

Credit risks

The Company does not have any material risks relating to a single customer or business partner. According to company policy for assuming credit risks, all customer credit ratings are periodically evaluated. Transactions with customers in the less mature geographical markets (e.g. Asia) are primarily secured by a guaranteed form of payment.

Strategy and objectives

Strategy

The primary strategy of BK Medical ApS is to target the intraoperative imaging markets for urological and surgical applications in the European, Asian and North American ultrasound markets by continuously developing and introducing new products that address these markets' needs. In addition, the Company is focused on gaining a foothold in adjacent procedure-driven markets. To support this strategy, the Company continues to strengthen its direct and indirect sales and distribution in the USA, Europe and China by expanding its sales organisation, and expanding the R/D capabilities.

To enable profitable growth, the Company leverages the sourcing, manufacturing and administrative resources of its parent Company, Analogic Corporation.

Sales and marketing activities are carried out by the Company's subsidiaries in Germany, Italy, Sweden, Belgium, and the UK as well as through dealer networks, primarily in Eastern Europe, Latin America, the Middle East and Asia corresponding to approximately 70 countries. On an on-going basis, BK Medical ApS considers the possibilities of expansion of relevant niche solutions, including distribution form, through strategic cooperation alliances or through acquisitions. The organisation is developed continuously to adapt to ever changing conditions.

Target and expectations for the year ahead

As mentioned above, the competition on the overall ultrasound market is continuously increasing. This is expressed through more aggressive marketing and ultimately lower prices resulting in increased pressure on margins. At the same time, there are indications of a certain consolidation where only the large market participants are expected to endure in the long term. As expressed by our strategy, it is BK Medical ApS' plan to expand into and develop other relevant surgical markets in order to create a basis for adequate future growth.

The forecast for 2019/20 shows revenue at a flat to mid-single digit organic growth rate. This is a realistic target when seen in the light of the investments in new products. The growth is primarily expected to take place in the existing core markets with new products.

The expectations are based on the assumption that the exchange rates for the currencies to which the Company is exposed, primarily USD, will remain unchanged.

Management's review (continued)

Target and expectations for the year ahead (continued)

Costs are budgeted to increase for 2019/20 compared to 2018/19 although lower than the expected increase in revenue, resulting in a higher EBIT Margin for 2019/20.

In 2018/19, capital expenditure decreased compared to prior years. It is expected that the Company's level of capital expenditure in property, plant and equipment for 2019/20 will remain at the same level, since no additional major investment are planned for development projects.

Furthermore, in 2018/19, capital expenditure related to intangible assets decreased compared to 2017/18. It is expected that the Company's level of capital expenditure in intangible assets for 2019/20 will increase due to investments in the new product platform for future ultrasound systems.

Basis of earnings

Research and development

Research and development is carried out by BK Medical ApS in Herlev for all ultrasound scanners. Expenses related to research and development activities increased by DKK 18.0 million in 2018/19 due to lower expenses related to an externally funded project that ended in 2017/18. Capitalisation of R&D projects was lower compared to 2017/18 due to the release of BK Medical's latest ultrasound scanner BKSpecto during the fiscal year 2017/18. The strategic commitment to new markets with increasing requirements on the products and their performance continues. These investments are primarily aimed at providing new platforms for future ultrasound scanners.

The majority of development activities are focused on the development of a new generation of ultrasound scanners and transducers that will help open new markets for BK Medical ApS.

Intellectual capital resources

The development, production and marketing of high-end technology ultrasound scanners demand highly skilled employees. Therefore, BK Medical ApS attaches great importance to recruiting, retaining and developing competent staff – e.g. through increased focus on HR functions and the introduction of a common set of values.

Unusual events

There have been no unusual events during the fiscal year.

Statutory report on corporate social responsibility

BK Medical ApS develops and markets human diagnostic ultrasound equipment, primarily for the urological and surgical market segments and, secondarily, for selected point-of-care markets, general Imaging and other markets.

The BK Medical ApS Code of Conduct is intended to promote ethical conduct in all Company affairs in accordance with our high standards of integrity, and to deter wrongdoing in compliance with all applicable laws and regulations

As a global company, BK Medical ApS is aware that there can be risks when operating in areas where approaches to human rights and anti-corruption may differ from Denmark. Breaches concerning human rights could

Management's review (continued)

Statutory report on corporate social responsibility (continued)

impact our ability to retain and attract employees and impact our reputation. Breaches regarding corruption and bribery could also impact our reputation. That is why we have a primary focus on these risks, including setting the tone at the top to align the values throughout the Group. As a development and sales company, our environmental impact is limited for which reason we consider it a lower risk. Consequently, we do not have a separate policy, but we follow existing rules and laws in this area. We are also not aware of any breaches regarding environment and climate in BK Medical ApS in 2018/19.

Human rights

We fully acknowledge our responsibility to respect human rights as set out in the International Bill of Human Rights and are committed to implementing the United Nations Guiding Principles on Business and Human Rights throughout our operations. Respect for the dignity of the individual and for the importance of each individual's human rights forms the basis of the behaviors we expect of every individual who works for us, either as a direct employee or indirectly through our supply chain. We do not accept any form of discrimination, harassment or bullying within BK Medical. To this end we require all of our managers to implement processes designed to ensure equality of opportunity and inclusion for all BK Medical employees. These include avoiding any form of forced, bonded or compulsory labour (or any other kind of modern slavery or human trafficking).

Goals and implementation

Our Code of conduct will have a section on respecting human rights. It is our goal that we will not experience issues related to non-compliance with human rights. We are not aware of any breaches concerning human rights in BK Medical ApS in 2018/19.

Ethics and anti-corruption

BK Medical ApS has a zero tolerance towards corruption and bribery, including means such as improper payments, bribes and kickbacks, and facilitation payments. BK Medical ApS is committed to complying with the United States Foreign Corrupt Practice Act (FCPA), export controls and comparable laws where BK Medical ApS engages in business. We require the same commitment from our employees, business partners and suppliers.

Goals and implementation

All employees and distributors receive guidelines on anti-corruption and bribery. It is our goal that we will not experience issues related to ethics and anti-corruption. We are not aware of any breaches concerning corruption and bribery in BK Medical ApS in 2018/19.

Workplace responsibilities

We are committed to maintaining a safe and healthy work environment by complying with applicable health and safety rules and practices. Furthermore, we encourage employees to raise work-related issues, questions or concerns. We value the talents, abilities and diversity of all employees and require all employment decisions (e.g. recruiting, hiring, training, promoting, and compensation) related to employees and applicants to be based on merit, qualifications, and job performance.

Management's review (continued)

Goals and implementation

To implement our workplace responsibilities, we focus on offering relevant training, internal courses and employee development interviews. We conclude that our activities have contributed to maintaining a good working environment in BK Medical ApS in 2018/19.

Policy regarding the Proportion of Gender in other Management Levels of BK Medical ApS

BK Medical ApS is committed to continue working towards and maintaining equal opportunities for women and men at all management levels within the Company. BK Medical ApS encourages talented male and female employees to pursue a career within the Company. In connection with recruitment, including recruitment at management level, it is BK Medical ApS' policy to meet the Company's needs for employees with the right skills and competences, regardless of gender, age, ethnicity, etc. When choosing between equally qualified candidates, the diversity among the employees is taken into consideration, as it is the aim that both genders attain representation at management levels of at least 30%. In connection with recruitment for managerial positions it must be ensured, where possible, that the candidates invited for interview include both men and women. The Company's focus on diversity among its employees, including at management levels, must be visible during recruitment.

The policy may be amended by the Board of Directors and should be interpreted in accordance with applicable equal rights and anti-discrimination legislation in Denmark, applicable at any given time.

We currently have less than 30% representation of the gender with lowest proportion at manager level. We are however, on level with the general proportion of gender for the company. We follow our policy of not discriminating when we hire for both management positions and regular employees. Since the proportion of each gender at manager level is consistent with the general proportion, no steps have been initiated this financial year.

Policy regarding the Proportion of Gender in the board of BK Medical ApS

The Company aims to continue the current strategy as it is the policy of BK Medical ApS to meet the Company's needs for board members with the right skills and competences, regardless of gender, age, ethnicity, etc. When choosing between equally qualified candidates, the diversity among the employees is taken into consideration, as it is the objective that both genders attain representation at board level of at least 20%.

Further, the Company continuously aims at ensuring that the board supports the inter-company relations by means of its composition which is currently made up by 2 members elected by the employees and 3 members elected by the general meeting, where two are also connected to the parent company: Chairman Brooks Edward West and Director Robert Joseph Patterson.

There is currently a minimum of 20% representation of each gender on the board, which falls within our policy, and therefore, no steps have been initiated this financial year.

Subsequent event

As of the report date, no significant events have occurred which are considered to have a material effect on the assessment of the annual report.

Accounting policies

The annual report of BK Medical ApS has been prepared in accordance with the provisions of the Danish Financial Statements Act that applies to large reporting class C enterprises.

The accounting policies are consistent with those of the prior year.

Reporting currency

The financial statements are presented in '000 Danish kroner.

Consolidated financial statements

In accordance to section 112(1) of the Danish Financial Statements Act, no consolidated financial statements have been prepared. The financial statements of BK Medical ApS and its group enterprises are included in the consolidated financial statements of the intermediate parent company, BK Medical Holding ApS.

Cash flow statement

In accordance to section 86(4) of the Danish Financial Statement Act and with the reference to the cash flow statement included in the consolidated financial statement of BK Medical Holding ApS, the Company has not prepared a cash flow statement.

Recognition and measurement

Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortization, provisions and reversals due to changed accounting estimates of amounts which were previously recognized in the income statement.

Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.

Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.

Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.

Accounting policies (continued)

Translation policies

Foreign currencies are translated with the exchange rates at the transaction date. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognised in financial income and expenses in the income statement.

Receivables, payables and other monetary items in foreign currencies that have not been settled at the balance sheet date are translated at the exchange rates at the balance sheet date. Any differences between the exchange rates at the balance sheet date and the transaction date rates are recognised in financial income and expenses in the income statement.

Fixed assets acquired in foreign currencies are measured at the transaction date rates.

Segment reporting

We identify a business as an operating segment if: i) it engages in business activities from which it may earn revenues and incur expenses; ii) its operating results are regularly reviewed by our chief operating decision maker who is our chief executive officer, and iii) it has available discrete financial information. We aggregate our operating segments into a reportable segment if the operating segments are determined to have similar economic characteristics and are similar in the nature of products and services, nature of production processes, type or class of customer for their products and services, product or service distribution method and, if applicable, nature of the regulatory environment. We have only one business segment: Ultrasound. For this reason, it is not relevant to provide segment information by business segment.

According to current statutory requirements, information on revenue is provided on geographical segments.

Income Statement

Revenue

Income from the sale of finished goods for resale and finished goods is recognised in revenue when transfer of the most significant rewards and risks to the buyer has taken place and provided that the income can be reliably measured and payment is expected to be received. The date of the transfer of the most significant rewards and risks is based on standardised terms of delivery based on Incoterms® 2010.

Revenue from the sale of services, comprising service contracts, is recognised in revenue on a straight-line basis as delivered as the services are delivered in the form of an indefinite number of actions over a specific period of time.

Revenue from software compensation is recognised as the company's IP assets are used.

Revenue is recognised exclusive of VAT and net of discounts relating to sales.

Cost of goods sold

Cost of goods sold comprises costs incurred to achieve revenue for the year. Cost comprises of materials, consumables, finished goods, goods for resale and depreciation etc. Moreover, amortisation of capitalised development cost is included.

Accounting policies (continued)

Sales- and distribution expenses

Sales- and distribution expenses comprise costs in the form of salaries to sales and distribution staff, advertising and marketing expenses, depreciation, etc.

Administrative expenses

Administrative expenses comprise expenses for management, administrative staff, office expenses, depreciation, etc.

Research- and development expenses

Development expenses comprise costs in the form of salaries to staff in the development department and research and development expenses that do not qualify for capitalization.

Public grants

Public grants given to cover expenses are recognised in the income statement as a reduction of research and development costs when it is probable that the enterprise complies with all the terms of the grant. Grants given to purchase assets are set off against the cost of the asset concerned.

Financial income and expenses

Financial income and expenses comprise interest, realised and unrealised exchange adjustments, dividend from subsidiaries as well as interest on extra payments and repayment under the on-account taxation scheme.

Dividend from investments in subsidiaries is recognised in the income statement in the financial year when the dividend is declared.

Tax on profit/loss for the year

Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity transactions is recognised directly in equity.

Any changes in deferred tax due to changes to tax rates are recognised in the income statement.

The Company is jointly taxed with the immediate Parent Company, BK Medical Holding ApS. The tax effect of the joint taxation is allocated to enterprises showing profits or losses in proportion to their taxable incomes (full allocation with credit for tax losses).

Interest on extra payments and repayment under the on-account taxation scheme are recognised in the income statement in financial income and expenses.

Accounting policies (continued)

Balance Sheet

Intangible assets

On initial recognition, intangible assets are measured at cost.

Development costs related to the Company's development of hardware and software comprise costs, salaries and amortisation directly or indirectly attributable to the Company's development activities.

Development projects that are clearly defined and identifiable, and where the technical feasibility, sufficient resources and a potential future market or development opportunities in the Company are evidenced, and where the Company intends to produce, market or use the project, are recognised as intangible assets provided that the cost can be measured reliably and that there is sufficient assurance that future earnings can cover production costs, selling costs and administrative expenses and development costs. Other development costs are recognised in the income statement when incurred.

Development costs that are recognised in the balance sheet are measured at cost less accumulated amortisation and impairment losses.

The amortisation of development costs is based on an estimate of the financial useful life of the individual projects and is calculated on a straight-line basis over 5 years.

Gains and losses on the disposal of development projects, patents and licenses are determined as the difference between the selling price less selling costs and the carrying amount at the date of disposal. Gains or losses are recognised in the income statement as other operating income or other operating costs, respectively.

Property, plant and equipment

Property, plant and equipment are measured at cost less accumulated depreciation and less any accumulated impairment losses.

Cost comprises the cost of acquisition and expenses directly related to the acquisition up until the time when the asset is ready for use.

Accounting policies (continued)

Property, plant and equipment (continued)

Depreciation based on cost reduced by any residual value is calculated on a straight-line basis over the expected useful lives of the assets, which are:

Land	Not depreciated
Production building	40 years
Plant and machinery	3-7 years
Other fixtures and fittings, tools and equipment	3-8 years

Depreciation is recognised in the income statement as cost of goods sold, sales- and distribution costs and administrative expenses, respectively.

Gains and losses on the disposal of property, plant and equipment are determined as the difference between the selling price less selling costs and the carrying amount at the date of disposal. Gains or losses are recognised in the income statement as other operating income or other operating costs, respectively.

Impairment of fixed assets

The carrying amounts of intangible assets and property, plant and equipment are reviewed on an annual basis to determine whether there is any indication of impairment other than that expressed by amortisation and depreciation.

If so, an impairment test is carried out to determine whether the recoverable amount is lower than the carrying amount and the asset is written down to its lower recoverable amount. This impairment test is performed on an annual basis for development projects in progress irrespective of any indication of impairment. The recoverable amount of the asset is calculated as the higher of net selling price and value in use. Where a recoverable amount cannot be determined for the individual asset, the assets are assessed in the smallest group of assets for which a reliable recoverable amount can be determined based on a total assessment.

Investments in subsidiaries

Investments in subsidiaries are measured at cost. Cost includes the consideration measured at fair value plus direct purchase costs. Where cost exceeds the recoverable amount, write-down is made to this lower value.

Accounting policies (continued)

Inventories

Inventories are measured at the lower of cost under standard cost method and net realisable value. Provisions are made for slow-moving and obsolete items. Goods for resale and consumables are measured at cost, comprising purchase price plus delivery costs.

The net realisable value of inventories is calculated as the sales amount less costs necessary to make the sale and is determined considering marketability, obsolescence and development in expected selling price.

Product is held by the sales force in the field both for sales and demonstration purposes. We classify and value such product based on the manner in which it is used by the sales force. To the extent that demonstration inventory is unsold after a period of a year, it is written down over its estimated remaining useful life of 36 months.

Receivables

Receivables are recognised in the balance sheet at amortised cost, which substantially corresponds to nominal value.

Write-downs for estimated bad debts are determined, based on a specific evaluation of the receivables. Write-downs are calculated as the difference between the carrying amount of receivables and the present value of the expected cash flows, including the realisable value of any collateral received.

Prepayments

Prepayments comprise prepaid expenses concerning subsequent financial years. Prepayments include prepaid rent, insurance premiums, exhibitions and leasing etc.

Cash

Cash comprise cash in banks.

Equity

Reserve for development costs

The reserve for development costs comprise recognized development costs, net of deferred tax. The reserve will be adjusted for the effect of amortization cost via appropriation of profit or loss. The reserve will be reduced or dissolved if the recognized development costs are no longer part of the Company's operations by transfer directly to the distributable reserves under equity. The reserve cannot be used to distribute dividends or cover losses.

Dividend

Dividend distribution proposed by Management for the year is disclosed as a separate item under equity.

Accounting policies (continued)

Provisions

Provisions are recognised when, as a result of past events, the Company has a legal or constructive obligation and it is probable that there may be an outflow of resources embodying economic benefits to settle the obligation. Provisions are measured at net realisable value. If the obligation is expected to be settled far into the future, the obligation is measured at fair value.

Deferred tax assets and liabilities

Deferred income tax is measured using the balance sheet liability method in respect of temporary differences arising between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes based on the intended use of the asset and settlement of the liability, respectively. Deferred tax assets, including the tax base of tax loss carry-forwards, are measured at the value at which the asset is expected to be realised, either by elimination in tax on future earnings or by set-off against deferred tax liabilities within the same legal tax entity.

Deferred tax assets are recognised at the expected value of their utilisation; either as a set-off against tax on future income or as a set-off against deferred tax liabilities.

Deferred tax is measured based on the tax rules and tax rates that will be effective under the legislation at the balance sheet date when the deferred tax is expected to crystallise as current tax. Any changes in deferred tax due to changes to tax rates are recognised in the income statement.

Current tax receivables and liabilities

Current tax liabilities and receivables are recognised in the balance sheet as the expected taxable income for the year adjusted for tax on taxable incomes for prior years and tax paid on account.

Financial liabilities

Financial liabilities are measured at amortised cost, substantially corresponding to net realisable value.

Deferred income

Deferred revenue is primarily comprised of maintenance and other service revenues for which payment has been received and for which services have not yet been rendered. In situations where collection of the receivable is not reasonably assured, the inventory is expensed upon shipment and the revenue is recognized as the cash is received.

Accounting policies (continued)

Financial ratios

Financial ratios are calculated in accordance with the Danish Finance Society's guidelines on the calculation of financial ratios "Recommendations and Financial Ratios".

The financial ratios stated in the survey of financial highlights have been calculated as follows:

Gross margin: $\text{Gross profit} / \text{Net revenue} * 100$

EBIT margin: $\text{Profit/loss before net financials (EBIT)} / \text{Net revenue} * 100$

Return on assets: $\text{Profit/loss before net financials} / \text{Total assets} * 100$

Solvency ratio: $\text{Equity} / \text{Total assets} * 100$

Return on equity: $\text{Net profit/loss for the year} / \text{Average equity in the year} * 100$

**Income statement
for the year ended 31 July**

	Notes	2018/19 12 months DKK'000	2017/18 12 months DKK'000
Revenue	1	407.902	406.187
Cost of goods sold	2,7,8	<u>-184.691</u>	<u>-159.656</u>
Gross margin		223.211	246.531
Sales- and distribution expenses	2,8	-48.909	-49.140
Research- and development expenses	2,8	-90.770	-72.717
Administrative expenses	2,8	<u>-19.000</u>	<u>-19.596</u>
Profit/loss before net financials		64.532	105.078
Financial income	3	5.325	4.855
Financial expenses	4	<u>-314</u>	<u>-266</u>
Profit/loss before tax		69.543	109.667
Tax for the year	5	<u>-9.261</u>	<u>-23.728</u>
Net profit/loss for the year	6	<u><u>60.282</u></u>	<u><u>85.939</u></u>

**Balance sheet
at 31 July**

	Notes	2018/19 12 months DKK'000	2017/18 12 months DKK'000
Assets			
Fixed assets			
Completed development projects		36.708	65.936
Development projects in progress		<u>10.587</u>	<u>6.165</u>
Intangible assets	7	<u>47.295</u>	<u>72.101</u>
Land and buildings		87.263	88.888
Plant and machinery		14.139	13.928
Other fixtures and fittings, tools and equipment		<u>2.156</u>	<u>3.870</u>
Property, plant and equipment	8	<u>103.558</u>	<u>106.686</u>
Investments in subsidiaries	9	18.583	18.583
Receivables from group enterprises	10	<u>7.618</u>	<u>7.601</u>
Investments		<u>26.201</u>	<u>26.184</u>
Total fixed assets		<u>177.054</u>	<u>204.971</u>
Current assets			
Inventories	11	<u>16.583</u>	<u>12.672</u>
Trade receivables		52.788	52.306
Receivables from group enterprises		162.208	58.755
Other receivables		476	2.765
Prepayments	12	<u>2.599</u>	<u>1.865</u>
Receivables		<u>218.071</u>	<u>115.691</u>
Cash		<u>3.782</u>	<u>34.375</u>
Total current assets		<u>238.436</u>	<u>162.738</u>
Total assets		<u>415.490</u>	<u>367.709</u>

**Balance sheet
at 31 July**

	Notes	2018/19 12 months DKK'000	2017/18 12 months DKK'000
Equity and liabilities			
Equity			
Share capital		64.225	64.225
Reserve for development cost		36.890	56.230
Retained earnings		215.793	136.159
Proposed dividend for the year		<u>15.000</u>	<u>15.000</u>
Total equity	13	<u>331.908</u>	<u>271.614</u>
Provisions			
Provisions for deferred tax	14	<u>2.672</u>	<u>30.788</u>
Total provisions		<u>2.672</u>	<u>30.788</u>
Liabilities			
Other payables	15	610	400
Deferred income	16	<u>5.505</u>	<u>3.331</u>
Long-term liabilities		<u>6.115</u>	<u>3.731</u>
Trade payables		5.865	7.261
Payables to group enterprises		1.693	2.186
Prepayments from customers		1.119	708
Corporation taxes		36.656	24.399
Other payables	15	25.792	24.511
Deferred income	16	<u>3.670</u>	<u>2.511</u>
Short-term liabilities		<u>74.795</u>	<u>61.576</u>
Total liabilities		<u>80.910</u>	<u>65.307</u>
Total equity and liabilities		<u>415.490</u>	<u>367.709</u>
Fees to the auditors appointed by the company in general meeting	17		
Contingent assets and liabilities and other financial obligations	18		
Related parties and ownership	19		
Subsequent events	20		

Notes

	2018/19 DKK'000	2017/18 DKK'000
Note 1. Revenue		
Segmentation of revenue on geographical area:		
Denmark	24.422	22.135
Scandinavia – other	15.210	11.919
Europe – other	103.263	96.964
USA	107.956	139.246
Asia, Pacific and rest of world	<u>157.051</u>	<u>135.923</u>
	<u><u>407.902</u></u>	<u><u>406.187</u></u>
Note 2. Staff costs		
Analysis of staff costs:		
Wages and salaries	101.192	96.393
Pension costs	7.383	6.700
Other social security costs	<u>1.791</u>	<u>1.624</u>
	110.366	104.717
Capitalized development cost (see note 7)	<u>-4.422</u>	<u>-10.138</u>
	<u><u>105.944</u></u>	<u><u>94.579</u></u>
Wages and Salaries, pensions, other social security expenses and other staff expenses are recognised in the following items:		
Cost of goods sold	9.678	8.367
Sales– and distribution expenses	23.034	21.014
Research- and development expenses	63.553	55.286
Administrative expenses	<u>9.679</u>	<u>9.912</u>
	<u><u>105.944</u></u>	<u><u>94.579</u></u>
Salaries and fees paid to the executive and supervisory boards:		
Executive board	3.259	3.898
Supervisory board	<u>0</u>	<u>0</u>
Salaries and fees paid to the executive and supervisory boards	<u><u>3.259</u></u>	<u><u>3.898</u></u>
Average number of employees	<u><u>130</u></u>	<u><u>123</u></u>

The executive board and other selected individuals were part of the Analogic stock compensation plan in 2017/18.

Notes (continued)

	2018/19 DKK'000	2017/18 DKK'000
Note 3. Financial income		
Interest receivable, group enterprises	364	283
Other interest receivable, exchange gains and similar income	<u>4.961</u>	<u>4.572</u>
	<u>5.325</u>	<u>4.855</u>
Note 4. Financial expenses		
Bank charges	<u>314</u>	<u>266</u>
	<u>314</u>	<u>266</u>
Note 5. Tax for the year		
Estimated income tax charge, excl. interest surcharges	20.392	25.747
Change in provision for deferred tax	<u>-5.373</u>	<u>-2.019</u>
	15.019	23.728
Prior year adjustments	<u>-5.758</u>	<u>0</u>
	<u>9.261</u>	<u>23.728</u>
Note 6. Appropriation of profit/loss		
Profit/loss to be appropriated:		
The executive board recommends the following appropriation of the profit/loss:		
Proposed dividend for the year	0	15.000
Dividend proposed during the year	0	28.500
Change to reserve for development costs due to amortization of capitalized development cost	-19.340	-21.006
Retained earnings/Accumulated loss	<u>79.622</u>	<u>63.445</u>
Total appropriation	<u>60.282</u>	<u>85.939</u>

Notes (continued)

Note 7. Intangible assets

	Completed development projects	Development projects in progress	Total
Cost			
Balance at 1/8 2018	178.711	6.165	184.876
Additions in the year	0	4.422	4.422
Transfers in the year	<u>0</u>	<u>0</u>	<u>0</u>
Cost at 31/7 2019	<u>178.711</u>	<u>10.587</u>	<u>189.298</u>
Amortisation			
Balance at 1/8 2018	112.775	0	112.775
Amortisation in the year	<u>29.228</u>	<u>0</u>	<u>29.228</u>
Amortisation at 31/7-2019	<u>142.003</u>	<u>0</u>	<u>142.003</u>
Carrying amount at 31/7 2019	<u>36.708</u>	<u>10.587</u>	<u>47.295</u>
Amortised over	<u>5 years</u>		

Management has not identified any evidence of impairment relative to the carrying amount of capitalized development projects.

Development projects

The company has capitalized internal development cost relating to the continuous development into our products, being scanners, transducers and accessories. We typically have one to two scanners and several transducers in development. For this fiscal year we have capitalized development cost for 5 transducers or accessories.

	2018/19 DKK'000	2017/18 DKK'000
Amortisation of intangible assets is recognised in the following items:		
Cost of goods sold	<u>29.228</u>	<u>26.931</u>
	<u>29.228</u>	<u>26.931</u>

Notes (continued)

Note 8. Property, plant and equipment

	Land and buildings	Plant and machinery	Other fixtures and fittings tools and equipment	Total
Cost				
Balance at 1/8 2018	136.758	44.933	19.892	201.583
Additions in the year	1.798	3.237	1.001	6.036
Disposals in the year	<u>0</u>	<u>760</u>	<u>2.458</u>	<u>3.218</u>
Cost at 31/7 2019	<u>138.556</u>	<u>47.410</u>	<u>18.435</u>	<u>204.401</u>
Depreciation				
Balance at 1/8 2018	47.870	31.005	16.022	94.897
Depreciation in the year	3.423	3.014	1.097	7.534
Depreciation of disposals and scrapped assets	<u>0</u>	<u>748</u>	<u>840</u>	<u>1.588</u>
Depreciation at 31/7 2019	<u>51.293</u>	<u>33.271</u>	<u>16.279</u>	<u>100.843</u>
Carrying amount at 31/7 2019	<u>87.263</u>	<u>14.139</u>	<u>2.156</u>	<u>103.558</u>

Management has not identified any evidence of impairment relative to the carrying amount of property, plant and equipment.

	2018/19 DKK'000	2017/18 DKK'000
Depreciations of property, plant and equipment are recognised in the following items:		
Cost of goods sold	3.257	2.305
Sales – and distribution expenses	556	1.114
Research- and development expenses	2.749	3.155
Administrative expenses	<u>972</u>	<u>993</u>
	<u>7.534</u>	<u>7.568</u>

Note 9. Investments in subsidiaries

	<u>Subsidiaries</u>
Cost	
Balance at 1/8 2018	18.583
Additions of enterprises	<u>0</u>
Cost at 31/7 2019	<u>18.583</u>

Notes (continued)

Analysis of the company's results of operations and equity, according to the most recent financial statements:

	<u>Domicile</u>	<u>Currency</u>	<u>Nominal capital</u>	<u>Interest (%)</u>	<u>Equity</u>	<u>Net profit/loss</u>
Group enterprises						
BK Medical Systems, Inc.	USA	USD	679	100	84.774	17.274
BK Medical G.m.b.H	GER	EUR	3.731	100	18.647	2.466
BK Medical Benelux N.V.S.A	BEL	EUR	463	100	8.025	1.274
BK Medical S.r.l	ITA	EUR	1.978	100	4.250	455
BK Medical AB	SWE	SEK	236	100	9.919	1.001
BK Ultrasound Limited	UK	GBP	9.413	100	<u>11.019</u>	<u>1.353</u>
					<u>136.634</u>	<u>23.824</u>

In the section above the annual published report for 2018/19 were used for UK, Belgium and Sweden. Germany and USA are based on non-published numbers for 2017/18. Italy is based on non-published numbers for 2018/19.

Note 10. Receivables from group enterprises

	<u>Receivables from group enterprises</u>
Cost	
Balance at 1/8 2018	<u>7.600</u>
Cost at 31/7 2019	<u>7.600</u>
Currency revaluations	
Revaluations at 1/8 2018	1
Revaluations in the year	<u>17</u>
Revaluations at 31/7 2019	<u>18</u>
Carrying amount at 31/7 2019	<u>7.618</u>

	2018/19	2017/18
	DKK'000	DKK'000

Note 11. Inventory

Raw materials and consumables	1.728	918
Finished goods and goods for resale	<u>14.855</u>	<u>11.754</u>
	<u>16.583</u>	<u>12.672</u>

Notes (continued)

	2018/19 DKK'000	2017/18 DKK'000
Note 12. Prepayments		
Prepaid insurance premiums	618	657
Prepaid exhibitions	412	319
Other prepayments	<u>1.569</u>	<u>889</u>
	<u><u>2.599</u></u>	<u><u>1.865</u></u>

Note 13. Statement of changes in equity

	Share capital	Reserve for development cost	Retained earnings/ Accumulated loss	Proposed dividend	Total
Balance at 1/8 2018	64.225	56.230	136.159	15.000	271.614
Exchange adjustment	0	0	13	0	13
Dividends distributed	0	0	0	0	0
Development cost capitalized in the year, net of deferred tax	0	3.449	-3.449	0	0
Transfer through appropriation of profit/loss	<u>0</u>	<u>-22.789</u>	<u>83.070</u>	<u>0</u>	<u>60.282</u>
Equity at 31/7 2019	<u><u>64.225</u></u>	<u><u>36.890</u></u>	<u><u>215.793</u></u>	<u><u>15.000</u></u>	<u><u>331.908</u></u>

The share capital consists of 64.225 shares of a nominal value of DKK 1.000. No shares carry any special rights.

There have been no changes in the share capital during the last 5 years.

Notes (continued)

	2018/19 DKK'000	2017/18 DKK'000
Note 14. Deferred tax provisions		
Balance at 1/8 2018	30.788	31.459
Adjustment of the deferred tax charge for the year in the income statement	<u>-28.116</u>	<u>-671</u>
Balance at 31/7 2019	<u><u>2.672</u></u>	<u><u>30.788</u></u>
 Deferred tax relates to:		
Intangible assets	10.405	15.862
Property, plant and equipment	4.101	3.312
Fixed assets investments	1.830	1.826
Trade receivable	-176	0
Accruals	<u>-2.019</u>	<u>-1.491</u>
	14.140	19.509
Accounting provision for uncertain tax positions	<u>-11.468</u>	<u>11.279</u>
	<u><u>2.672</u></u>	<u><u>30.788</u></u>

A tax rate of 22% has been applied to the statement of deferred tax both in the current and in the past year.

Note 15. Long-term liabilities

Of the long-term liabilities, DKK 0 thousand falls due for payment after more than 5 years after the balance sheet date.

Breakdown of certain liabilities by long-term and short-term liabilities:

	Falling due between <u>1 and 5 years</u>	Falling due after more <u>than 5 years</u>	Total long-term liabilities at <u>31/7 2019</u>	Falling due within <u>1 year</u>	Total
Other payables	<u>610</u>	<u>0</u>	<u>610</u>	<u>25.792</u>	<u>26.402</u>
	<u><u>610</u></u>	<u><u>0</u></u>	<u><u>610</u></u>	<u><u>25.792</u></u>	<u><u>26.402</u></u>

Note 16. Deferred income

Deferred income is mainly relating to extended warranty and of income where the revenue recognition criteria as to collectability has not been met.

Notes (continued)

	2018/19 DKK'000	2017/18 DKK'000
Note 17. Fees to the auditors appointed by the company in general meeting		
Fee for statutory audit	330	349
Fee for other assurance engagements	55	66
Fee for tax advice	0	25
Fee for non-audit services	<u>0</u>	<u>150</u>
	<u><u>385</u></u>	<u><u>590</u></u>

	2018/19 DKK'000	2017/18 DKK'000
Note 18. Contingent assets and liabilities and other financial obligations		
Rental agreements and leases		
Lease obligations under operating leases. Total future lease payments:		
Within a year	758	679
Between 1 and 5 years	<u>709</u>	<u>813</u>
	<u><u>1.467</u></u>	<u><u>1.492</u></u>

Contingent liabilities

Through its bankers, the Company has as per 31 July 2019 issued payment, advance and performance guarantees totaling DKK 584 thousand (2017/18: DKK 360 thousand).

The Danish group companies are jointly and severally liable for tax on the Group's jointly taxed for the income year 2018/19.

Notes (continued)

Note 19. Related parties

Transactions with related parties

No transactions on non-arm's length are disclosed in the financial statements.

Controlling interest

	<u>Basis</u>
Altaris Capital Partners, LLC 10 East 53rd Street, 31st Floor New York, NY 10022 USA	Ultimate parent company
BK Medical Luxembourg S.á.r.l. 5 rue Guillaume Kroll 1882 Luxembourg	Intermediate parent company
BK Medical Holding ApS Mileparken 34 DK-2730 Herlev	Immediate parent company

Consolidated Financial Statements

The Company is included in the Consolidated Financial Statements of the Parent Company BK Medical Holding ApS and BK Medical Luxembourg S.á.r.L.

The Consolidated Financial Statements of BK Medical Holding ApS may be obtained at the following address:

BK Medical Holding ApS
Mileparken 34
DK-2730 Herlev

The consolidated financial statements for Altaris Capital Partners LLC are not made available for the public.

Note 20. Subsequent events

After the balance sheet date, no significant events have occurred which are considered to have a material effect on the assessment of the Annual Report.